| Ytd | -26.41% | |
| 1y | -53.98% |
| Open | 3.04 | Prev Close | 3.08 | Low | 2.98 | High | 3.07 | Mkt Cap | 1.38B |
| Vol | 6.04M | Avg Vol | 19.93M | EPS | -1.20 | P/E | -2.57 | Forward P/E | -3.78 |
| Beta | 1.00 | Short Ratio | 7.99 | Inst. Own | 68.86% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-05 | 50-d Avg | 3.31 | 200-d Avg | 4.01 | 1yr Est | 7.25 |
RXRX News
Amova Asset Management Americas Inc. decreased its position in shares of Recursion Pharmaceuticals,
In the closing of the recent trading day, Recursion Pharmaceuticals (RXRX) stood at $2.89, denoting
In the most recent trading session, Recursion Pharmaceuticals (RXRX) closed at $3.34, indicating a +
Recursion Pharmaceuticals has yet to prove that its approach to developing medicines is superior. Sa
Recursion Pharmaceuticals (RXRX) closed the most recent trading day at $3.72, moving 3.13% from the
Oncology innovation is reshaping cancer care as AI, immunotherapy and targeted therapies fuel pipeli
Two stocks that have fallen out of favor and one hot stock that was one of Thursday's biggest losers
Dyne Therapeutics is advancing a clinical-stage platform specifically targeting genetically driven n
Moderna is evolving from a COVID-19 vaccine specialist into a multi-product firm with major oncology
Anthropic launches Claude Science for researchers as PwC data shows AI mentions in pharma M&A de
Artificial intelligence is reshaping nearly every industry, but some of its biggest opportunities ar
Recursion harnesses AI for large-scale drug discovery, while Summit's betting on a single oncology c
Recursion Pharmaceuticals' approach to drug discovery could advance the industry. Fiverr is implemen
Recursion Pharmaceuticals (RXRX) closed at $3.23 in the latest trading session, marking a +2.22% mov
The latest trading day saw Recursion Pharmaceuticals (RXRX) settling at $3.18, representing a -3.34%
Recursion Pharmaceuticals, Inc. is advancing REC-1245, an RBM39 degrader, in the DHALIA trial in sol
Recursion Pharmaceuticals (RXRX) closed the most recent trading day at $3.06, moving 5.12% from the
Recursion Pharmaceuticals, Inc. (RXRX) Presents at Goldman Sachs 47th Annual Global Healthcare Confe
Recursion Pharmaceuticals (RXRX) reported earnings 30 days ago. What's next for the stock?
Two AI-driven disruptors, one biotech-focused, one software-first, post double-digit growth but dive
Salt Lake City, UT, June 02, 2026 (GLOBE NEWSWIRE) -- Recursion (Nasdaq: RXRX), a leading clinical-s
Here's a look at the earnings calendar for the week ahead, including reports from Nvidia, Joby,
U.S. stock futures traded lower this morning. Here are some big stocks recording gains in today’s pr
Gainers Panbela Therapeutics, Inc. (NASDAQ: PBLA) shares jumped 53% to close at $0.58 on Friday.
On Wednesday, 807 companies reached new 52-week lows.
On Friday, 1043 companies hit new 52-week lows.
During Thursday, 849 stocks hit new 52-week lows.